These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 31288974)

  • 41. Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: a randomized double-blind pilot study.
    Barak Y; Plopski I; Tadger S; Paleacu D
    Int Psychogeriatr; 2011 Nov; 23(9):1515-9. PubMed ID: 21492498
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
    Daiello LA
    Med Health R I; 2007 Jun; 90(6):191-4. PubMed ID: 17633594
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antipsychotic treatment patterns in Alzheimer's disease patients with agitation: a cohort study using the UK clinical practice research datalink.
    Tran CT; Bøg M; Collings SL; Johnson M; Qizilbash N; Lind S; Baker RA; Jørgensen KT
    Curr Med Res Opin; 2022 Mar; 38(3):409-416. PubMed ID: 35068266
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Escitalopram.
    Aronson S; Delgado P
    Drugs Today (Barc); 2004 Feb; 40(2):121-31. PubMed ID: 15045034
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Resumption of food and fluid intake in Alzheimer's disease with severe apathy following intravenous citalopram.
    Hellen F; Supprian T; Salamon T; Lange-Asschenfeldt C
    Psychiatry Clin Neurosci; 2012 Feb; 66(1):82. PubMed ID: 22250618
    [No Abstract]   [Full Text] [Related]  

  • 46. Pharmacological Management of Agitation and Aggression in Alzheimer's Disease: A Review of Current and Novel Treatments.
    Liu CS; Ruthirakuhan M; Chau SA; Herrmann N; Carvalho AF; Lanctôt KL
    Curr Alzheimer Res; 2016; 13(10):1134-44. PubMed ID: 27137221
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer's disease.
    Siddique H; Hynan LS; Weiner MF
    J Clin Psychiatry; 2009 Jun; 70(6):915-8. PubMed ID: 19422762
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Narrative Review of Studies Comparing Efficacy and Safety of Citalopram with Atypical Antipsychotics for Agitation in Behavioral and Psychological Symptoms of Dementia (BPSD).
    Qasim HS; Simpson MD
    Pharmacy (Basel); 2022 Jun; 10(3):. PubMed ID: 35736776
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interventions for Neuropsychiatric Symptoms in Neurocognitive Impairment Due to Alzheimer's Disease: A Review of the Literature.
    McClam TD; Marano CM; Rosenberg PB; Lyketsos CG
    Harv Rev Psychiatry; 2015; 23(5):377-93. PubMed ID: 26332220
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
    Azorin JM; Llorca PM; Despiegel N; Verpillat P
    Encephale; 2004; 30(2):158-66. PubMed ID: 15107719
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A perfect storm in the emergency department.
    Yee AH; Wijdicks EF
    Neurocrit Care; 2010 Apr; 12(2):258-60. PubMed ID: 20012708
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacogenetics of citalopram-related side effects in children with depression and/or anxiety disorders.
    Amitai M; Kronenberg S; Carmel M; Michaelovsky E; Frisch A; Brent D; Apter A; Chen A; Weizman A; Fennig S
    J Neural Transm (Vienna); 2016 Nov; 123(11):1347-1354. PubMed ID: 27324805
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Escitalopram in adolescent major depression.
    Schaller JL; Rawlings DB
    MedGenMed; 2005 Jan; 7(1):6. PubMed ID: 16369311
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients.
    Pollock BG; Mulsant BH; Rosen J; Sweet RA; Mazumdar S; Bharucha A; Marin R; Jacob NJ; Huber KA; Kastango KB; Chew ML
    Am J Psychiatry; 2002 Mar; 159(3):460-5. PubMed ID: 11870012
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Serotonin augmentation therapy by escitalopram has minimal effects on amyloid-β levels in early-stage Alzheimer's-like disease in mice.
    von Linstow CU; Waider J; Grebing M; Metaxas A; Lesch KP; Finsen B
    Alzheimers Res Ther; 2017 Sep; 9(1):74. PubMed ID: 28899417
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Agitation and aggression in Alzheimer's disease: an update on pharmacological and psychosocial approaches to care.
    Gallagher D; Herrmann N
    Neurodegener Dis Manag; 2015; 5(1):75-83. PubMed ID: 25711456
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Successful Use of Escitalopram for the Treatment of Visual Hallucinations in Patients With Parkinson Disease.
    Bergman J; Lerner PP; Sokolik S; Lerner V; Kreinin A; Miodownik C
    Clin Neuropharmacol; 2017; 40(6):246-250. PubMed ID: 29059136
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Escitalopram versus citalopram: the surprising role of the R-enantiomer.
    Sánchez C; Bøgesø KP; Ebert B; Reines EH; Braestrup C
    Psychopharmacology (Berl); 2004 Jul; 174(2):163-76. PubMed ID: 15160261
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Investigational drugs for treating agitation in persons with dementia.
    Garay RP; Citrome L; Grossberg GT; Cavero I; Llorca PM
    Expert Opin Investig Drugs; 2016 Aug; 25(8):973-83. PubMed ID: 27232589
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial.
    Fox C; Crugel M; Maidment I; Auestad BH; Coulton S; Treloar A; Ballard C; Boustani M; Katona C; Livingston G
    PLoS One; 2012; 7(5):e35185. PubMed ID: 22567095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.